MUMBAI -- India's third-largest drugmaker by sales, Lupin, has diversified into biosimilars -- cheaper versions of expensive biotech drugs -- in a bid to stimulate growth amid a slowdown in recent years.
Companies
India's Lupin targets generic potential of biotech drugs
Expiring patents open window for launch in Japan and Europe by year end
.jpg?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
A worker conducts an inspection at Lupin's biosimilar plant in Pune, India. (Photo courtesy of Lupin)
Read Next
Latest on Companies
